Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer

Authors: Canavese G.2; Venturini M.1; Rosso R.1; Del Mastro L.1; Garrone O.3; Angiolini C.1; Merlano M.3; Bergaglio M.1; Tolino G.1; Lambiase A.4; Baldini A.4

Source: Annals of Oncology, Volume 13, Number 4, 26 April 2002 , pp. 546-552(7)

Publisher: Oxford University Press

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Purpose

Capecitabine is an oral fluoropyrimidine with considerable activity and minimal myelosuppression and alopecia. This phase I study evaluated the addition of capecitabine to epirubicin/docetaxel combination therapy as first-line treatment for advanced breast cancer.

Patients and methods

Twenty-three female patients with advanced breast cancer received capecitabine (765–1060 mg/m2 twice daily on days 1–14 of a 3-week treatment cycle) in combination with epirubicin and docetaxel (75 mg/m2 i.v. on day 1).

Results

The maximum tolerated dose of capecitabine was 985 mg/m2 and the principal dose-limiting toxicity was febrile neutropenia. No grade 3/4 anemia or thrombocytopenia occurred. There were no grade 4 non-hematological events and grade 3 events other than alopecia were rare. Alopecia occurred in all patients and treatment cycles, and asthenia occurred in all patients and in 84% of treatment cycles. Other frequent adverse events included nausea, vomiting, fever, paresthesia and elevated transaminase levels. An objective response to treatment was observed in 91% (95% confidence interval 72% to 99%) of patients.

Conclusions

The addition of capecitabine to docetaxel/epirubicin combination therapy provides a well-tolerated and active first-line chemotherapy regimen in patients with advanced breast cancer, and merits phase II/III evaluation.

Keywords: Key words: advanced breast cancer; capecitabine; docetaxel; epirubicin; phase I

Document Type: Original article

Affiliations: 1: Medical Oncology and 2: Surgical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova; 3: Division of Medical Oncology, Ospedale S. Croce e Carle, Cuneo; 4: Roche, Milano, Italy

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$39.53 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A